Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...9293949596979899100101102...401402»
  • ||||||||||  Review, Journal:  Obstructive Sleep Apnea and Venous Thromboembolism: Unraveling the Emerging Association. (Pubmed Central) -  Oct 2, 2023   
    The review concludes by outlining promising future directions in this field, calling for deeper exploration of specific oxidative stress markers, understanding the temporal dynamics of oxidative stress, validation through translational studies in humans, and the development of targeted therapeutic interventions. By advancing our understanding of the intricate relationship between oxidative stress and skeletal muscle atrophy, this review contributes to paving the way for innovative strategies to address muscle wasting and improve muscle health.
  • ||||||||||  Review, Journal:  Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression? (Pubmed Central) -  Oct 2, 2023   
    Unfortunately, there is no standardized cure, apart from doing more physical activity and embracing a balanced diet, but newly discovered substances start being considered. In this review, authors try to give an overview addressing principal pathways of sarcopenia and offer critical features of various possible interventions.
  • ||||||||||  Review, Journal:  Osteoporotic vertebral body fractures (Pubmed Central) -  Sep 29, 2023   
    For the mostly elderly patients, it is important to treat the underlying disease and to address associated problems such as frailty and sarcopenia. To meet this growing medical and socio-economic challenge, a
  • ||||||||||  Review, Journal:  Advances in the relationship between temporal muscle thickness and prognosis of patients with glioblastoma: a narrative review. (Pubmed Central) -  Sep 29, 2023   
    As a result, patients with glioblastoma may use temporal muscle thickness as a potential marker to correlate with the course and fate of their disease. This narrative review highlights and defines the viability of using temporal muscle thickness as an independent predictor of survival in glioblastoma patients, and it evaluates recent research findings on the association between temporal muscle thickness and prognosis of glioblastoma patients.
  • ||||||||||  Journal:  Cirrhosis-related sarcopenia may not resolve after liver transplantation. (Pubmed Central) -  Sep 29, 2023   
    Interestingly, sarcopenia did not influence post-transplant outcomes. Future prospective studies are needed to further understand the natural course of sarcopenia post-LT to guide interventions aiming at reversing post-LT sarcopenia.
  • ||||||||||  Enrollment closed, Trial primary completion date:  Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C (clinicaltrials.gov) -  Sep 28, 2023   
    P3,  N=96, Active, not recruiting, 
    Our study suggests a potential functional gut microbiome-host interaction linking sarcopenia with the altered gut microbiomes, BA profiles and amino acids pointing towards a potential mechanistic interplay in understanding sarcopenia pathogenesis. Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2023 --> Aug 2023
  • ||||||||||  Journal:  Body Composition, Coronary Microvascular Dysfunction, and Future Risk of Cardiovascular Events Including (Pubmed Central) -  Sep 28, 2023   
    In a predominantly female cohort of patients without flow-limiting coronary artery disease, deficient muscularity, not excess adiposity, was independently associated with CMD and future adverse outcomes, especially heart failure. In patients with suspected ischemia and no obstructive coronary artery disease, characterization of lean body mass and coronary microvascular function may help to distinguish obese phenotypes at risk for cardiovascular events.
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date:  RENAMUS 19: FGF19 and Chronic Kidney Disease (clinicaltrials.gov) -  Sep 28, 2023   
    P=N/A,  N=170, Recruiting, 
    In patients with suspected ischemia and no obstructive coronary artery disease, characterization of lean body mass and coronary microvascular function may help to distinguish obese phenotypes at risk for cardiovascular events. Not yet recruiting --> Recruiting | Trial completion date: Mar 2026 --> Feb 2027 | Trial primary completion date: Mar 2022 --> Feb 2027
  • ||||||||||  Journal, Machine learning:  Machine Learning Applications in Sarcopenia Detection and Management: A Comprehensive Survey. (Pubmed Central) -  Sep 28, 2023   
    However, it acknowledges the limitations of these models and systems, including inefficiencies in handling large volumes of medical data and the lack of dynamic selection capability. In conclusion, the paper provides a comprehensive summary of current sarcopenia research, emphasizing the potential of modern technologies in enhancing the detection and management of the condition while also highlighting the need for further research to address challenges in standardization, data management, and effective technology use.
  • ||||||||||  Review, Journal:  Rehabilitation: Neurogenic Bone Loss after Spinal Cord Injury. (Pubmed Central) -  Sep 28, 2023   
    This review article will discuss the pathophysiology and risk factors of muscle and bone loss after SCI, including the mechanisms that may lead to muscle and bone loss after SCI. This review will also focus on current and future pharmacological and non-pharmacological therapies for reducing or eliminating neurogenic bone loss following SCI.
  • ||||||||||  Review, Journal:  Systematic review: Sarcopenia in paediatric inflammatory bowel disease. (Pubmed Central) -  Sep 27, 2023   
    Nutritional intervention may have a positive effect on LM and FFM. Future research should focus on standardizing the terminology and methodologies used in assessing body composition and investigating sarcopenia in diseased and matched healthy control cohorts in adequately powered studies with a longitudinal design.
  • ||||||||||  Retrospective data, Journal:  The longitudinal associations of sarcopenia definitions with functional deterioration: a comparative study. (Pubmed Central) -  Sep 27, 2023   
    Our findings suggested that the definition of probable sarcopenia identified by not standard, but population-specific thresholds more reliably predicted longitudinal deterioration of functionality in older outpatients. This finding might be considered as evidence supporting the use of population-specific cut-offs when the concern is sarcopenia diagnosis.
  • ||||||||||  Journal:  Phase angle is associated with sarcopenic obesity in post-stroke patients. (Pubmed Central) -  Sep 26, 2023   
    Our study suggests the importance of assessing for muscle loss in conjunction with lung function decline when evaluating individuals with tobacco exposure. The phase angle was associated with sarcopenic obesity, and the cutoff values of the phase angle that could predict sarcopenic obesity were 4.29
  • ||||||||||  Clinical, Journal:  Effects of resistance training on sarcopenia in patients with intestinal failure: A randomized controlled trial. (Pubmed Central) -  Sep 26, 2023   
    In this randomized clinical trial, we observed that 4 weeks of resistance training was associated with improved ASMI, physical performance, biochemical parameters (including IGF-1, prealbumin, and hemoglobin), and body composition in IF patients with sarcopenia. Resistance training can be recommended as a simple and effective method to improve sarcopenia in patients with IF.
  • ||||||||||  Journal:  Challenges and physiological implications of sarcopenia in children and youth in health and disease. (Pubmed Central) -  Sep 26, 2023   
    This study suggests that in KTR, higher coffee consumption is associated with increased adiposity, specially, central adiposity and lower muscle quality, but is not related with the other evaluated parameters. Longitudinal evaluation of sarcopenia expression and the underlying physiological and lifestyle factors contributing to pediatric sarcopenia are important to understand to ensure effective rehabilitation strategies can be developed and to avoid the adverse clinical consequences in children.